Cannabis Holds Promise In Treating Autism: GCANRx (OTCPK: GCAN) Is Taking It To The Next Level With Its Novel Neuropsychiatric Cannabinoid Therapy
When it comes to autism spectrum disorder (ASD), the treatments available are coming up short. The pharmaceutical therapies on the market only work for some patients and come with unwanted potential side effects such as obesity and altered hormone production. Behavioral therapies can help, but can be intensive, long-term and costly. Behavioral therapies alone can cost $17,000 to $100,000 per year, depending on the severity of the ASD and the type of insurance the family has.
At last check, ASD, which has no cure, affects more than five million people in the U.S. and over 75 million worldwide, witnessing a quadruple increase in the decade to 2020. Today, ASD can be found in one in 36 children. The cost of caring for someone with ASD is projected to hit $461 billion by 2025, up 72% from $268 billion in 2015. It also takes a toll on the family. One study found families with an autistic member experience more health problems and lower overall family well-being.
Cannabis To The Rescue?
One area that holds promise in treating ASD is the use of cannabis, specifically cannabidiol (CBD). Cannabidiol (CBD) is found in hemp and cannabis sativa plants. When consumed orally or applied topically, it helps regulate mood, immune functions and pain. Research has shown it can also help alleviate many of the systems of ASD. As a result, CBD …